GlassScriptPhysician profile
Mohamed E Salem
NPI 1497882369
$395,623.91
in general payments reported to CMS, 2019-2025
15 companies · $21K in 2025
The $21K reported for 2025 was more than what 88% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73K · 2020: $7,630 · 2021: $31K · 2022: $81K · 2023: $153K · 2024: $29K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $102K · Consulting Fee: $70K · Travel and Lodging: $27K · Food and Beverage: $3,343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $101,828.00 |
| Consulting Fee | $70,407.50 |
| Travel and Lodging | $27,258.42 |
| Food and Beverage | $3,343.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $140,830.60 | 2021-2025 | Imfinzi, Tagrisso |
| Taiho Oncology, INC. | $86,730.32 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $75,734.28 | 2019-2024 | Opdivo |
| Seagen INC. | $22,516.30 | 2022-2023 | Tukysa |
| Array Biopharma INC | $16,266.34 | 2020-2025 | Braftovi, Mektovi |
| Daiichi Sankyo INC. | $14,313.30 | 2021 | |
| Exelixis INC. | $10,727.00 | 2019-2022 | |
| Pfizer INC. | $10,282.61 | 2022-2023 | |
| Incyte Corporation | $7,355.11 | 2025 | |
| Amgen INC. | $3,245.00 | 2023 | Lumakras |
| Beone Medicines USA, INC. | $2,400.00 | 2025 | Tevimbra |
| Blueprint Medicines Corporation | $1,890.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $1,875.00 | 2021 | |
| Merck Sharp & Dohme LLC | $1,350.00 | 2020 | |
| Genentech USA, INC. | $108.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamed Salem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.